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STRUCTURED SUMMARY 47 
Aims 48 
Ischaemia-reperfusion injury (IRI) causes impaired endothelial function and is a major 49 
component of the adverse effects of reperfusion following myocardial infarction. Rotigaptide 50 
increases gap junction conductance via connexin-43. We tested the hypothesis that rotigaptide 51 
reduces experimental myocardial infarction size, and ameliorates endothelial IRI in humans. 52 
 53 
Methods 54 
Myocardial infarction study: porcine MI was achieved by catheter-induced occlusion of the 55 
left anterior descending artery. In a randomized double-blind study, rotigaptide (n=9) or 56 
placebo (n=10) was administered intravenously as a 10-min bolus prior to reperfusion and 57 
continuously during 2 hours of reperfusion. Myocardial infarction size (IS) was assessed as 58 
proportion of the area at risk (AAR). Human translational study: forearm IRI was induced in 59 
the presence or absence of intra-arterial rotigaptide. In a randomized double-blind study, 60 
forearm arterial blood flow was measured at rest and during intra-arterial infusion of 61 
acetylcholine (5-20 µg/min; n=11) or sodium nitroprusside (2 - 8 mg/min; n=10) before and 62 
after intra-arterial infusion of placebo or rotigaptide, and again following IRI.  63 
 64 
Results 65 
Myocardial infarction study: Rotigaptide treatment was associated with a reduction of infarct 66 
size (IS/AAR[%]: 18.7±4.1 [rotigaptide] vs. 43.6±4.2 [placebo], P=0.006). Human 67 
translational study: Endothelium-dependent vasodilatation to acetylcholine was attenuated 68 
after ischaemia-reperfusion in the presence of placebo (P=0.007), but not in the presence of 69 
rotigaptide (P=NS). Endothelium-independent vasodilatation evoked by sodium nitroprusside 70 
was unaffected by IRI or rotigaptide (P=NS). 71 
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 72 
Conclusions 73 
Rotigaptide reduces myocardial infarction size in a porcine model and protects from IRI-74 
related endothelial dysfunction in man. Rotigaptide may have therapeutic potential in the 75 
treatment of myocardial infarction. 76 
 77 
 78 
 79 
 80 
 81 
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 84 
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What is already known about this subject: 97 
• Ischaemia-reperfusion injury reflects the paradoxical injury associated with 98 
restoration of blood flow to an ischaemic organ.  99 
 100 
• Connexins may play a pivotal role in ischaemia-reperfusion injury. 101 
 102 
• A means to prevent this paradoxical injury should translate into improved clinical 103 
outcomes for a wide range of patients including those treated for ischaemic stroke, 104 
myocardial infarction or for those undergoing solid organ transplantation. 105 
 106 
 107 
What this study adds: 108 
• Rotigaptide, a modulator of connexin 43 phosphorylation, is associated with a marked 109 
reduction in porcine myocardial infarction size when administered at the time of 110 
reperfusion. 111 
 112 
• Ischaemia-reperfusion injury reduces endothelium-dependent vasodilatation in the 113 
human forearm arterial circulation, but this effect is not seen in the presence of 114 
rotigaptide. 115 
 116 
• These findings provide important direction for the development of connexin 117 
modulators designed for the limitation of clinically important ischaemia-reperfusion 118 
injury. 119 
 120 
 121 
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 122 
INTRODUCTION 123 
Acute arterial occlusion may lead to end-organ ischaemia and, ultimately, infarction. 124 
Although treatment is usually directed at prompt restoration of flow in the occluded artery, 125 
reperfusion may trigger further injury beyond that induced by ischaemia alone. Importantly, 126 
such ischaemia-reperfusion injury (IRI) can markedly reduce the benefits of reperfusion 127 
therapies employed in a variety of clinical settings, including myocardial infarction and stroke 128 
[1].  129 
 130 
Impaired endothelium-dependent vasomotor function is an important manifestation of IRI [2-131 
4]. Disrupted endothelium-dependent vasomotion may not just be a surrogate marker for IRI 132 
but also of prime importance in the pathophysiological process. Such reperfusion injury may 133 
be prevented by prior exposure to intermittent sublethal ischaemia [5,6] but the mechanism 134 
underlying the preconditioning phenomenon remains incompletely defined. As such, despite 135 
being an obvious therapeutic target to protect from the important deleterious effects 136 
associated with vascular reperfusion, no single physical preconditioning strategy or 137 
pharmacologic agent has been identified to fulfill this role.  138 
 139 
Gap junctions may be pivotal in IRI [7]. They form an aqueous pore through which small 140 
hydrophilic molecules and ionic charge may pass between neighbouring cells. Each gap 141 
junction comprises two hemichannels, composed of connexin (Cx) subunits that allow the gap 142 
junction to open and close depending upon phosphorylation status [8]. Cx43 is particularly 143 
abundant in myocardial tissue [9] and, in addition to a role in the mediation of vasodilator 144 
responses evoked by endothelium-derived hyperpolarising factor (EDHF) [10], Cx43 appears 145 
to be important in the mediation of ischemia-reperfusion injury as well as the preconditioning 146 
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process [11,12].  147 
 148 
Rotigaptide (ZP-123) is a hexapeptide drug that was originally developed as an anti-149 
arrhythmic agent. It promotes electrical coupling between ventricular myocytes by increasing 150 
gap junction conductance [13,14], potentially via alterations in the phosphorylation status of 151 
Cx43 [15] and it increases the number of gap junctions in the ischaemic myocardium.[16] The 152 
open-state probability of Cx43 is depressed by acidosis [17] and during reperfusion after 153 
ischemia [18] suggesting that rotigaptide’s properties will be most suited to these 154 
environments. Indeed, rotigaptide’s anti-arrhythmic activity is more potent in conditions of 155 
metabolic stress [14]. 156 
 157 
We examined the effects of rotigaptide upon myocardial infarction size when administered 158 
during reperfusion in a porcine model. We subsequently assessed the potential protective 159 
effects of rotigaptide in the human forearm arterial circulation subjected to ischaemia and 160 
reperfusion.  161 
 162 
METHODS  163 
Porcine Myocardial Infarction Study 164 
Animals and Study Design 165 
Thirty Danish Landrace pigs (Paaskehoejgaardcentret, Aarhus, Denmark) weighing 166 
approximately 15 kg were studied. Animals were treated as humane as possible according to 167 
the principles stated in Danish law on animal experiments and the recommendations of 168 
ARRIVE.  169 
 170 
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Animals were anaesthetised with midazolam 50mg s.c. and ketamine 250 mg s.c., intubated 171 
and ventilated at 4.5 L/min with a 50/50 mixture of atmospheric air and oxygen. Anaesthesia 172 
was maintained with an infusion of pentobarbital 50 mg/mL at 5 mL/h. Ventilatory alterations 173 
were made to maintain physiological levels of oxygenation and electrolyte balance and were 174 
guided by hourly blood gas measurements. Temperature was kept between 36.5°C and 38.0°C 175 
with the use of a heating blanket. Blood pressure was maintained at above 80 mmHg with 176 
epinephrine as needed. Ventricular fibrillation and sustained ventricular tachycardia were 177 
treated with DC cardioversion. Intravenous heparin 4,000 IU at baseline followed by 2,000 178 
IU/h was administered to maintain anticoagulation.  179 
 180 
Hemodynamic Assessments 181 
Pressure derived indices of ventricular function were acquired using a 5F pressure catheter 182 
positioned in the left ventricle. Pressures were sampled via high-fidelity analogue to digital 183 
hardware at 500 Hz to dedicated data acquisition software (Notocord→, France). We used 184 
maximum pressure development over time (dP/dtmax, mmHg·sec-1), maximum negative 185 
pressure development over time (dP/dtmin, mmHg·sec-1) and end systolic pressure (ESP, 186 
mmHg) as indices of cardiac function. 187 
 188 
Administration of rotigaptide 189 
Pigs were randomized to intravenous infusion of either rotigaptide (1 µg/kg bolus at time of 190 
reperfusion + 10 µg/kg/h infusion IV during 2 h of reperfusion) or placebo, (bolus + 191 
continuous infusion IV). Researchers were blinded to the presence of rotigaptide or placebo. 192 
 193 
Induction of myocardial infarction 194 
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A standard 6F angioplasty guide catheter was used to introduce a guidewire into the left 195 
anterior descending artery (LAD) under fluoroscopic guidance. A 2 mm angioplasty balloon 196 
was positioned immediately distal to the first diagonal and inflated to achieve vessel 197 
occlusion for 40 min. LAD occlusion distal to the first diagonal was confirmed by 198 
angiography. After 40 min, the balloon was deflated. Reperfusion was for 120 min, after 199 
which median sternotomy was performed.  200 
 201 
Assessment of myocardial infarction size and area at risk 202 
A suture was applied immediately distal to the first diagonal artery, and the heart was 203 
perfusion-stained with intra-atrial injection of 10% Evans blue dye before euthanasia and 204 
excision of the heart to determine the area at risk. Hearts were frozen at -80 ºC for 20 min and 205 
cut into 7 mm thick transverse sections parallel to the atrioventricular groove. Sections were 206 
subsequently incubated in 0.09 mol/L sodium phosphate buffer containing 1.0 % triphenyl 207 
tetrazolium chloride (TTC; Sigma-Aldrich Chemie Gmbh, Munich, Germany) and 8 % 208 
dextran for 20 min at 37 °C in order to demarcate viable from infarcted tissue. Slices were 209 
weighed before scanning on a flatbed scanner and traced to determine the final infarct size. 210 
The total slice area, the area at risk, and the infarcted area were measured by computer-211 
assisted planimetry. After normalization for the weight of the tissue slices, the size of the area 212 
at risk as percent of the left ventricle and the infarct size expressed as percent of the area at 213 
risk were calculated (Figure 1). 214 
 215 
Human Translational Study 216 
This study was performed with the approval of the Lothian Research Ethics Committee 217 
(08/S1101/45) in accordance with the Declaration of Helsinki and with the written informed 218 
consent of each subject.  219 
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 220 
 221 
 222 
Subjects 223 
Healthy non-smokers were recruited into the study. Participants were excluded if they had 224 
clinically significant conditions including hypertension, hyperlipidemia, diabetes mellitus, 225 
asthma or coagulopathy. No participant had suffered a recent infective or inflammatory 226 
condition, nor had they taken any medication in the 7 days prior to the study. On the day of 227 
study, participants fasted and abstained from caffeine for at least 4 h and from alcohol for 24 228 
h. Subjects attended for two study visits, at least two weeks apart. 229 
 230 
Drugs 231 
Pharmaceutical grade acetylcholine (Novartis Ltd., Middlesex, UK), sodium nitroprusside 232 
(Hospira Inc., CA, USA) and rotigaptide (American Peptide Inc., CA., USA) were dissolved 233 
in physiological saline.  234 
 235 
Forearm venous occlusion plethysmography and ischaemia 236 
All subjects underwent cannulation of the brachial artery with a 27 standard wire gauge 237 
(SWG) steel needle under controlled conditions. All studies were performed with patients 238 
lying supine in a quiet, temperature controlled (22–24 ºC) room. The intra-arterial infusion 239 
rate was kept constant at 1 mL/min throughout all studies. Forearm blood flow was measured 240 
in the infused and non-infused arms by venous occlusion plethysmography using mercury-in-241 
silastic strain gauges as described previously [19,20]. Supine heart rate and blood pressure 242 
were monitored at intervals throughout each study using a semi-automated non-invasive 243 
oscillometric sphygmomanometer. 244 
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 245 
Ischaemia reperfusion injury was induced in the non-dominant arm by cuff inflation to 200 246 
mmHg for 20 min in the presence or absence of intra-arterial rotigaptide (25 nmol/min [15.4 247 
µg/min]). Protocol A: Bilateral arterial forearm blood flow was measured in eleven volunteers 248 
at rest and during intra-arterial infusion of acetylcholine ([ACh] 5-20 µg/min) before and after 249 
intra-arterial infusion of placebo/rotigaptide and post IR injury (Figure 2). Baseline venous 250 
blood samples were collected for haematology characteristics. Protocol B was identical to 251 
protocol A except the endothelium-independent vasodilator sodium nitroprusside ([SNP] 2-8 252 
µg/min) was used in place of acetylcholine (Figure 2). Ten volunteers completed this part of 253 
the study. 254 
 255 
Data Analysis and Statistics 256 
Forearm plethysmographic data were analyzed as described previously (Newby et al., 1997). 257 
Variables are reported as mean ± SEM and analyzed using repeated measures ANOVA with 258 
post-hoc Bonferroni corrections and two-tailed Students t-test as appropriate. Statistical 259 
analysis was performed with GraphPad Prism (GraphPad Software Inc., La Jolla, CA, USA) 260 
and statistical significance taken at the 5% level. All analysis was performed by an 261 
investigator blinded to the treatment groups.  262 
 263 
The authors had full access to the data and take responsibility for its integrity. All authors 264 
have read and agree to the manuscript as written. 265 
 266 
RESULTS 267 
Porcine Myocardial Infarction Study 268 
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Nineteen pigs completed the study protocol. Nine received rotigaptide and ten received 269 
placebo. Eleven of the initial thirty pigs failed to complete the study protocol due to refractory 270 
arrhythmia  following ischemia-reperfusion and were not included in the analysis. The 271 
incidence of refractory arrhythmia was not specific to either group of animals (5 in rotigaptide 272 
group, 6 in placebo group).  273 
 274 
Heart rate, maximal rate of rise of left ventricular pressure (dP/dtmax) and maximum left 275 
ventricular pressure were not different between groups at baseline, during ischaemia, and at 276 
any point following the administration of rotigaptide/placebo until the end of the study (Table 277 
1).  278 
 279 
Rotigaptide treatment was associated with a marked reduction in myocardial infarction size 280 
(IS) as a percentage of area at risk (AAR) (18.7 ± 4.1% vs. 43.6 ± 4.2%, P=0.006; in  281 
rotigaptide vs controls, respectively) (Figure 3). The AAR as a percentage of the left ventricle 282 
(LV) was not different between the two groups (26.8 ± 2.1% vs. 28.4 ± 2.1%, P=NS;  283 
rotigaptide vs controls). 284 
 285 
Human Translational Study 286 
Ischaemia reperfusion injury was well tolerated by all subjects with no adverse events. There 287 
were no differences in baseline clinical characteristics (including heart rate, blood pressure, 288 
haematocrit, haemoglobin and cholesterol) between volunteers in Protocol A (assessment of 289 
endothelium-dependent vasomotor responses to acetylcholine [ACh]) and Protocol B 290 
(assessment of endothelium-independent vasomotor responses to sodium nitroprusside [SNP]) 291 
(P=NS; data on file). 292 
 293 
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There was no difference in baseline forearm blood flow between visits in either Protocol A or 294 
Protocol B (P=NS, data on file). ACh and SNP evoked dose-dependent forearm arterial 295 
vasodilatation (P=NS, for all, ANOVA) that was not affected by co-infusion of rotigaptide 296 
(P=NS, ANOVA, data on file).  297 
 298 
In protocol A, IR injury caused substantial impairment of ACh-induced vasodilatation 15 min 299 
following reperfusion and 45 min after reperfusion (P=0.007 and P=0.05, respectively; 300 
ANOVA) in the absence of rotigaptide (Figure 4). This impairment of vasomotor function, 301 
relative to baseline, was not seen in the presence of rotigaptide 15 min after reperfusion 302 
(P=NS, ANOVA, Figure 4) and by 45 min after reperfusion blood flow responses to ACh in 303 
those receiving rotigaptide were greater than prior to ischemia and reperfusion (P=0.01, 304 
ANOVA, Figure 4). In protocol B, endothelium-independent vasodilatation evoked by SNP 305 
was unaffected by IR injury, both in the presence and the absence of rotigaptide (P=NS, 306 
ANOVA, Figure 5).  307 
  308 
DISCUSSION 309 
We have demonstrated that rotigaptide, a modulator of connexin 43 phosphorylation, is 310 
associated with a marked reduction in porcine myocardial infarction size when administered 311 
at the time of reperfusion. Furthermore, and for the first time in man, we have demonstrated 312 
the powerful protection that rotigaptide affords the human arterial vasculature at the time of  313 
ischaemia-reperfusion injury. These complementary studies highlight the pivotal role for 314 
healthy endothelial function in vascular homeostasis, including the limitation of ischaemic 315 
and reperfusion injury following acute arterial occlusion. Our findings provide important 316 
direction for the pharmaceutical development of connexin modulators designed for the 317 
limitation of clinically important ischaemia-reperfusion injury. 318 
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  319 
To examine the therapeutic utility of rotigaptide, we examined its effects in a clinically 320 
relevant animal model of myocardial infarction. In this closed-chest porcine model, the 321 
administration of rotigaptide at the time of reperfusion was associated with a reduction in 322 
infarction size. Indeed we observed a reduction of infarction size by approximately 43% when 323 
expressed relative to the area at risk. Hennan and colleagues previously demonstrated the 324 
cardioprotective effect of rotigaptide administered to dogs subjected to a one-hour period of 325 
coronary artery occlusion in an open chest model. A bolus dose of rotigaptide was 326 
administered 10 min prior to reperfusion and then by continuous infusion over a four-hour 327 
period. They demonstrated a dose-dependent reduction of infarct size as well as reduced 328 
ventricular arrhythmia burden [16]. Porcine coronary anatomy is understood to better reflect 329 
that of humans with a less prominent network of collateral vessels than that found in dogs. 330 
Furthermore, it can be argued that the closed chest model better replicates spontaneous 331 
myocardial infarction and avoids the confounding effects of instrumentation of the chest and 332 
handling of the heart. Haugan and colleagues demonstrated that the administration of 333 
rotigaptide at the time of onset of myocardial ischaemia in rats reduced infarct size in a model 334 
of myocardial infarction without reperfusion assessed after three weeks [21]. Whilst this study 335 
was the first to shed light upon the potential benefits of rotigaptide in myocardial infarction, it 336 
did not assess the effects of rotigaptide upon reperfusion injury. Furthermore, the 337 
administration of the drug at the onset of ischaemia cannot be considered a strategy easily 338 
translated to acute myocardial infarction but might rather inform its utility at the time of a 339 
more predictable ischaemia insult such as is encountered during solid organ transplantation. 340 
Danegaptide is an analogue of rotigaptide recently developed primarily to provide oral bio-341 
availability [22]. Whilst our results compare favourably with those seen with the 342 
administration of this agent, albeit in an open-chest study of reperfused porcine myocardial 343 
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infarction [23], it remains to be seen whether there is a therapeutic advantage of one agent 344 
over the other. Indeed, in the acute setting the requirement for an orally available drug is 345 
probably not as pressing as it would be in a non-emergent chronic setting. 346 
 347 
Having demonstrated the effect of rotigaptide in porcine myocardial infarction we assessed 348 
the effects of rotigaptide in human ischaemia-reperfusion injury. We have previously shown 349 
that Cx43 is required for the mediation of endothelium-derived hyperpolarising factor 350 
(EDHF) vasodilatation of human subcutaneous resistance vessels ex vivo [10]. Furthermore, 351 
we have also shown that, in the forearm arterial circulation of healthy men, rotigaptide has no 352 
effect on basal vascular tone and nor does it enhance endothelium-dependent vasodilatation 353 
[24]. However, in the in vivo healthy circulation, the open-state probability of Cx43 is likely 354 
to be high and efforts directed to further opening of Cx43 may be futile. Phosphorylation is 355 
enhanced at times of physiologic stress and acidosis, and Cx43 may thus be more likely to be 356 
in a closed state [25]. During ischaemia, IRI and acidosis, rotigaptide may counteract the 357 
usual effects of this environment to re-open channels of communication via Cx43. Therefore, 358 
in the current setting of ischaemia-reperfusion injury we hypothesised that the vascular effects 359 
of rotigaptide would be apparent and protective [26].  360 
 361 
Consistent with the previous demonstration of ischemia reperfusion injury in the human 362 
forearm circulation, a 20-min period of ischemia evoked a significant and specific impairment 363 
of endothelial vasomotor function [2]. There was a decline in the vasodilator response to the 364 
endothelium-dependent agonist acetylcholine. However, when the ischaemic insult was 365 
applied in the presence of rotigaptide, the deleterious effects of reperfusion on endothelial 366 
function were absent. Indeed, when assessed 15 and 45 min following reperfusion, endothelial 367 
vasomotor responses were preserved in the presence of rotigaptide. Neither rotigaptide nor 368 
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ischemia-reperfusion injury altered the blood flow response to the endothelium-independent 369 
vasodilator, sodium nitroprusside reinforcing the endothelial specificity of the IRI effect, and 370 
of rotigaptide. 371 
 372 
In addition to its potential utility in the setting of acute myocardial infarction, the clinical use 373 
of such an agent could be extended to a wide range of other pathophysiologic processes, 374 
including in the treatment of acute stroke or for administration at the time of solid organ 375 
transplantation. We believe that the accumulating data, including that presented here, make a 376 
strong case for the assessment of rotigaptide’s effects in a randomised controlled trial, 377 
particularly to assess its role in the reperfusion strategy for the treatment of acute myocardial 378 
infarction. 379 
 380 
Limitations 381 
We have demonstrated a clear beneficial effect of rotigaptide upon myocardial infarction size 382 
and have shown that rotigaptide has relevant protective effects in the human vasculature. 383 
These complementary studies do not, however, provide categorical proof that the limitation of 384 
infarct size is afforded by a protective endothelial effect or by some other protective non-385 
endothelial mechanism, either locally within the myocardium or via a paracrine process. We 386 
believe that the maintenance of healthy endothelial function including vasomotion, anti-387 
inflammatory activity and endogenous fibrinolysis is of central importance in rotigaptide’s 388 
protective effects. Indeed, the capacity for vasodilatation to allow the rapid washout of toxic 389 
metabolites, diminished production of reactive oxygen species, the capacity for dissolution of 390 
micro-thrombi and appropriate local anti-inflammatory activity remain critical for the 391 
limitation of reperfusion injury. However, it is perhaps as important to note that rotigaptide’s 392 
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potential for myocardial protection is not offset by some otherwise unrecognised toxic effect 393 
upon human endothelial function.  394 
 395 
In order to control for potential effects of rotigaptide upon vasomotor responses to agonists in 396 
the absence of IRI, the initial administration of rotigaptide was prior to the induction of 397 
ischaemia. Subsequent administration of rotgpatide/placebo was at the the time of 398 
reperfusion. By employing ths design, we confirmed that rotigaptide does not have a non-399 
specific effect upon blood flow responses to acetylcholine or sodium nitroprusside in the 400 
absence of IRI. However, it might be argued that the protective effects of rotigaptide seen in 401 
this study include a contribution from pre- as well as post-conditioning. Whilst we cannot 402 
fully exclude a contribution of pre-conditioning to the protection afforded by rotigaptide in 403 
this context, our porcine study highlights the protective effects of rotigaptide when 404 
administered only at the time of reperfusion (post-conditioning). Post-ischaemic conditioning 405 
is most relevant to the treatment of acute myocardial infarction but pre-conditioning may have 406 
a role in the protection of IRI at the time of solid organ transplatation or coronary bypass and 407 
is of clinical relevance. It is of note that physical (cuff-induced remote ischemia) pre-408 
conditioning has been disappointing in the setting of cardiopulmonary bypass [27,28] but 409 
pharmacological strategies have, to date, received less attention in major clinical trials. 410 
 411 
 412 
CONCLUSIONS 413 
Rotigaptide is associated with a marked reduction in myocardial infarction size after 414 
reperfusion in a porcine model. Furthermore, it provides important protection from the 415 
deleterious endothelial effects of ischaemia reperfusion therapy in man. The utility of 416 
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rotgaptide and related agents hold clinical promise for use in the clinical treatment of acute 417 
myocardial infarction in man and warrant further clinical study in this setting. 418 
 419 
 420 
 421 
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FIGURE LEGENDS 571 
Figure 1. 572 
Left ventricular myocardial slices stained with Evans Blue (area NOT at risk) and triphenyl 573 
tetrazolium chloride (TCC). Evans blue dye statining (dark red) delineates area not at risk 574 
from infarction (upper regions in these representative slices; left panel = rotigaptide treated 575 
animal, right panel = placebo). TTC staining bright red = viable tissue; white colour = 576 
infarcted tissue. 577 
 578 
 579 
Figure 2. 580 
Human translational study schedule of drug administration and ischemia/reperfusion timings. 581 
Ach: acetylcholine (Protocol A); SNP: sodium nitroprusside (Protocol B) 582 
 583 
 584 
Figure 3. 585 
Final myocardial infarction size (IS) expressed as a proportion of the area at risk (AAR); P = 586 
0.006, placebo vs rotigaptide (ANOVA). 587 
 588 
 589 
Figure 4. 590 
Forearm arterial vasomotor responses to intra-arterial acetylcholine, in the presence and 591 
absence of rotigaptide, before and after ischaemia-reperfusion injury. 2-way ANOVA 592 
baseline blood flow responses at baseline versus 15 min (left panels) or 45 min (right panels) 593 
following reperfusion. 594 
 595 
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Figure 5. 596 
Forearm arterial vasomotor responses to intra-arterial sodium nitroprusside, in the presence 597 
and absence of rotigaptide, before and after ischaemia-reperfusion injury. 2-way ANOVA 598 
baseline blood flow responses at baseline versus 15 min (left panels) or 45 min (right panels) 599 
following reperfusion. 600 
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TABLE 1 
 
  
HR (min-1) 
 
dP/dtmax (mmHg·s-1) 
 
 ESP (mmHg)  
 
dP/dtmin (mmHg·s-1) 
  
Placebo 
 
Rotigaptide 
 
Placebo 
 
Rotigatide 
 
Placebo 
 
Rotigaptide 
 
Placebo 
 
Rotigaptide 
         
Baseline 66 (17) 68 (13) 1920 (367) 2050 (504) 127 (14) 127 (14) -2862 (835) -2320 (562) 
0 min  post-
ischemia 
79 (26) 66 (10) 1655 (250) 1503 (284) 109 (12) 108 (13) -2284 (861) -1846 (525) 
1 min post 
ischemia 
152 (31) 134 (23) 1335 (358) 1555 (817) 108 (10) 86 (22) -1391 (541) -1375 (789) 
5 min post 
ischemia 
108 (28) 114 (23) 1736 (204) 1502 (480) 81 (15) 93 (14) -1898 (832) -1676 (861) 
30 min post 
ischemia 
104 (19) 106 (20) 1613 (197) 1609 (383) 86 (13) 97 (10) -1960 (665) -1749 (559) 
60 min post 
ischemia 
113 (14) 99 (16) 1515 (116) 1623 (551) 89 (11) 100 (7) -2056 (755) -2129 (955) 
120 min post 
ischemia 
88 (23) 96 (21) 1396 (266) 1423 (338) 101 (15) 103 (8) -2669 (1737) -1888 (603) 
Table 1: Porcine haemodynamic measurements.  
Mean (SD). HR: heart rate; dP/dtmax: Maximum positive pressure development over time; ESP: End-systolic pressure. Maximum negative 
pressure development over time. P = NS for all, placebo vs. rotigaptide (ANOVA).  
 
 
